Global Urokinase for Injection Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

According to our (Global Info Research) latest study, the global Urokinase for Injection market size was valued at US$ 322 million in 2025 and is forecast to a readjusted size of US$ 486 million by 2032 with a CAGR of 6.1% during review period.
The urokinase injection market refers to the clinical and commercial use of injectable urokinase (urokinase for injection)—a “clot-dissolving” medicine used in hospitals to break down unwanted blood clots. Urokinase works by acting on the body’s natural fibrinolytic system: it converts plasminogen into plasmin, and plasmin then breaks down fibrin clots (and also affects fibrinogen and some other plasma proteins). Because urokinase is given by injection/infusion and can cause serious bleeding, its use is typically limited to settings where doctors can monitor patients closely (emergency departments, intensive care units, catheter labs, interventional radiology suites, vascular surgery wards, and specialized stroke or thrombosis centers).
In practical terms, the market is defined by where and how urokinase injection is used. In some jurisdictions, product labeling and clinical practice include use for pulmonary embolism (blood clots in the lungs), for catheter-directed thrombolysis in peripheral arteries or graft occlusions, and for restoring patency of intravenous catheters blocked by clotted blood or fibrin. This “hospital procedure drug” positioning is important: urokinase injection is not a long-term prevention drug like oral anticoagulants; it is more often a time-sensitive rescue therapy or a procedure-support drug used when a clot is already causing acute risk or blocking a device.
A key part of the market definition is also the dosage form and supply chain. Urokinase products are commonly supplied as a sterile lyophilized (freeze-dried) powder that must be reconstituted before use. These factors make urokinase different from many small-molecule injectables: producers must manage complex upstream cell culture, purification, sterile fill-finish, and strict quality control, and buyers care about lot consistency and supply reliability.
In 2025, global Urokinase for Injection production reached approximately 15.6 million Units, with an average global market price of around US$ 20.1 per Units. The global single-line production capacity ranges from 350 to 500 K Units per year. The industry's gross profit margin is approximately 25%-35%.
On market trends, one broad trend is that thrombolysis is being shaped by newer thrombolytic agents, improved imaging, and more interventional procedures. In acute ischemic stroke, for example, many global guidelines focus on intravenous alteplase (and increasingly tenecteplase as an alternative in some systems) within defined time windows, and mechanical thrombectomy has expanded in selected patients. This matters for urokinase because it changes where urokinase is positioned: in many countries, urokinase is not the primary stroke thrombolytic, while in others it is used as a lower-cost or locally available option. A recent review notes that urokinase has been approved and used in China for years and that Chinese guidance has recommended intravenous urokinase within certain time windows for acute ischemic stroke, with commonly cited dosing ranges (for example 1,000,000–1,500,000 IU in that context). So, the stroke segment shows a “two-track” trend: in some regions, practice is consolidating around rt-PA/tenecteplase and thrombectomy pathways, while in other regions, urokinase remains relevant due to access, cost, and local evidence bases.
A second trend is the growth of catheter use in modern medicine, which tends to expand the catheter-clearance opportunity for thrombolytics, including urokinase. Central venous catheters and other long-term lines are widely used for chemotherapy, parenteral nutrition, long courses of IV antibiotics, and repeated blood draws. The clinical literature describes catheter occlusion as a frequent complication and reviews thrombolytic options for restoring patency. In that review, several thrombolytic agents (including recombinant urokinase) are discussed with reported catheter clearance rates and time-to-clearance outcomes, and the paper also notes that thrombolytic prophylaxis in some studies reduced catheter occlusion incidence. Even if individual studies vary, the practical market implication is straightforward: as the number of patients dependent on long-term catheters rises (cancer care, home infusion, complex pediatrics, dialysis pathways), hospitals place higher value on reliable, fast methods to reopen lines and avoid line replacement procedures.
A third trend is a procedural shift toward targeted therapy in vascular care. For some vascular occlusions, clinicians may prefer catheter-directed approaches that localize treatment at the clot, often aiming to improve efficacy while limiting systemic exposure and bleeding risk. Urokinase has a history of use in catheter-directed settings (for example, peripheral arterial and graft thromboembolic occlusion described in product monographs). At the same time, competition is intense: other thrombolytics (alteplase, tenecteplase, reteplase in certain contexts) and mechanical strategies (aspiration, thrombectomy devices, angioplasty/stenting) all influence whether a hospital uses urokinase, which dose, and for which patients. This competitive pressure pushes the urokinase market toward niches where it has clear operational or economic advantages (availability, protocol familiarity, cost, or suitability for a specific catheter-clearance workflow).
This report is a detailed and comprehensive analysis for global Urokinase for Injection market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Urokinase for Injection market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Urokinase for Injection market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Urokinase for Injection market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Urokinase for Injection market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Urokinase for Injection
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Urokinase for Injection market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Syner-Med, Wanhua Biochem, Jiangxi Haoran Bio-Pharma, Jiangsu Aidea Pharmaceutical, Techpool, Microbic Biosystems, LIVZON, Wuhan Humanwell Pharma, Tianjin Biochem Pharma, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Urokinase for Injection market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
10000-100000IU
100000-1000000IU
Others
Market segment by Clinical Use
Pulmonary Embolism Thrombolysis
Deep Vein Thrombosis
Peripheral Arterial Occlusion Thrombolysis
Catheter / Cannula Occlusion Clearance
Others
Market segment by Administration Approach
Systemic Infusion
Catheter-directed Thrombolysis (CDT)
Intracatheter Dwell / Lock Technique
Market segment by Purity
Standard Clinical Grade
High-purity / Low-impurity Grade
Low Endotoxin / Low Bioburden Specifications
Market segment by Application
Hospital
Clinic
Others
Major players covered
Syner-Med
Wanhua Biochem
Jiangxi Haoran Bio-Pharma
Jiangsu Aidea Pharmaceutical
Techpool
Microbic Biosystems
LIVZON
Wuhan Humanwell Pharma
Tianjin Biochem Pharma
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Urokinase for Injection product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Urokinase for Injection, with price, sales quantity, revenue, and global market share of Urokinase for Injection from 2021 to 2026.
Chapter 3, the Urokinase for Injection competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Urokinase for Injection breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Urokinase for Injection market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Urokinase for Injection.
Chapter 14 and 15, to describe Urokinase for Injection sales channel, distributors, customers, research findings and conclusion.